key: cord-0807576-ugq3hirr authors: Savino, Manuela; Santhakumaran, Shalini; Evans, Katharine M; Steenkamp, Retha; Benoy-Deeney, Fran; Medcalf, James F; Nitsch, Dorothea title: Outcomes of patients with COVID-19 on kidney replacement therapy: a comparison among modalities in England date: 2021-09-04 journal: Clin Kidney J DOI: 10.1093/ckj/sfab160 sha: 264d5b6be0a9ab5f1ba6157a2aacfaef80e8e3e6 doc_id: 807576 cord_uid: ugq3hirr BACKGROUND: Chronic kidney disease (CKD) is a recognised risk factor of poor outcomes from COVID-19. METHODS: This retrospective cohort study used the UK Renal Registry (UKRR) database of people on kidney replacement therapy (KRT) at the end of 2019 in England and who tested positive for SARS-CoV-2 between 01/03/2020 and 31/08/2020, to analyse incidence and outcomes of COVID-19 among different KRT modalities. Comparisons with 2015-2019 mortality data were used to estimate excess deaths. RESULTS: 2,783 individuals on KRT tested positive for SARS-CoV-2. Patients from more deprived areas (most deprived vs least deprived HR 1.20, 95% CI 1.04-1.39) and those with diabetes compared to those without (HR 1.51, 95% CI 1.39-1.64) were more likely to test positive. Approximately 25% of in-centre haemodialysis and transplanted patients died within 28 days of testing positive, compared to 36% of those on home therapies. Mortality was higher in those aged ≥80 years compared to those aged 60-79 years (OR 1.71, 95% CI 1.34-2.19) and much lower in those listed for transplantation compared to those not listed (OR 0.56, 95% CI 0.40-0.80). Overall, excess mortality in 2020 for people on KRT was 36% higher than the 2015-2019 average. Excess deaths peaked in April 2020 at the height of the pandemic and were characterised by wide ethnic and regional disparities. CONCLUSIONS: The impact of COVID-19 on the English KRT population highlights their extreme vulnerability and emphasises the need to protect and prioritise this group for vaccination. COVID-19 has widened underlying inequalities in people with kidney disease making interventions that address health inequalities a priority. Coronavirus disease 2019 (COVID-19), a highly contagious zoonosis caused by an RNA beta-coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started as an epidemic in Wuhan in 2019, and has since become a pandemic, 1 imposing a huge burden on public health globally. 2 To date (7 April 2021), the worldwide number of confirmed cases of coronavirus is over 100 million and in Europe, the number of deaths attributed to COVID-19 is about 800,000. 3 Chronic kidney disease (CKD) is a recognised risk factor of poor outcomes from COVID-19. 4,5 A UK cross-sectional survey of 17,278,392 adults registered with a general practice and who had at least one year of follow-up before 1 February 2020, reported a hazard ratio of COVID-19 related death for people with CKD of 1.57 (95% CI 1.51-1.64). 6 Likewise, the recently validated COVID-19 risk calculator highlights the importance of reduced kidney function and the very high risk of death for people with stage 5 CKD and on kidney replacement therapy (KRT). 7 However, the numbers of people on dialysis and transplantation in this study were too small to investigate differences in risk between KRT modalities. Our previous retrospective cohort analysis in England and Wales 8 focused only on people treated with in-centre haemodialysis (ICHD) and similar to a small Scottish study 9 reported an approximate 75% survival rate for people with COVID-19 on dialysis. The aims of this retrospective cohort study are to (i) describe the incidence of COVID-19 infection, (ii) to compare the outcomes between KRT modalities in England during the first wave of the pandemic between March and August 2020, and (iii) to estimate the excess mortality related to the pandemic using a comparison with 2015-2019 data. This study is a retrospective cohort analysis of all adults in the UK Renal Registry (UKRR) database who were receiving KRT at an English renal centre on 31 December 2019, still alive on 1 March 2020, who tested positive for SARS-CoV-2 between 01/03/2020 and 31/08/2020, and who had not opted out from using their data. The NHS Demographics Batch Service was used to obtain dates of death for the cohort as at 13 January 2021; mortality analyses considered death up to 28 days after the test date. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 pandemic. Excess deaths were compared across English regions and demographics, grouping all months together. All analyses were conducted using SAS version 9.4, 11 and 95% confidence intervals (95% CI) are reported throughout this paper. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 At the end of 2019, there were 55,799 adult patients on KRT in England not on the national NHS data opt-out register. After excluding those who died before 1 March 2020 (n=898) and those without a valid NHS number (n=106), this left 54,795 who were included in the study cohort ( Supplementary Fig. 1 ). Of patients included, 43% were on dialysis. The median age of patients on in-centre haemodialysis (ICHD) was higher than that of patients on home therapies (HT -peritoneal dialysis [PD] and home haemodialysis [HHD]) and with a transplant (67.1 vs 55.6 years). Among dialysis patients, 20% were listed for transplantation at the end of 2019 (Table 1) . From 1 March to 31 August 2020, 5% (2,783) of the study cohort tested positive for SARS-CoV-2 ( Table 2 ). The vast majority became infected in the first three months of the pandemic between March and May 2020 (Supplementary Table 1) , and only 7% became infected between June and August 2020. The cumulative percentage of patients who tested positive for SARS-CoV-2 was much higher among those on ICHD, reaching about 11% at the end of August 2020. The corresponding percentages for transplanted and HT patients were much lower, at 2 and 4%, respectively ( Fig.1 ). Looking at the cohort of people with COVID-19 on KRT, 76% were on ICHD, 24% were of Asian ethnic background and 56% were from the lowest two deprivation quintiles. Only 16% of dialysis patients with COVID-19 were on the transplant list and there was a higher proportion of positive patients with diabetes as PRD, especially among those on ICHD and PD ( Table 2 ). Of the positive cases occurring between March and May, only 17% occurred in transplant patients, increasing to 37% between June and August. This increase may be attributable to the discontinuation of the shielding policy in June. Notably, the incidence of COVID-19 remained higher among Asian people and those with higher socio-economic deprivation between June and August (Supplementary Table 1 ). The adjusted analysis showed that the main risk factor for testing positive was diabetic status as PRD (Fig. 2) , with a 51% higher risk among patients with diabetes compared to those without. The risk of testing positive also appeared to be higher among patients from more deprived areas. Conversely, it was lower among younger patients (HR in 18-39 years age group 0.64, 95% CI 0.54-0.75 compared to 60-79 years age group) and patients transplanted or listed for transplantation compared to those not listed (HR listed 0.83, 95% CI 0.73-0.93) ( Fig. 2 ). Modality differences varied across ethnic groups (p-value for ethnicity-modality interaction= 0.0002). Patients of White ethnicity were in general at lower risk of positivity than other ethnic groups, and the differences were larger in magnitude amongst transplant patients ( Supplementary Fig. 2 ). People on ICHD were at higher risk of positivity compared to people on transplant or home therapies, particularly in White patients. A higher risk in HT compared to transplant was only seen in White patients ( Supplementary Fig 3) . By contrast, there were no important differences by sex. Just 2% of the cohort were excluded from the adjusted analyses due to missing ethnicity, deprivation or PRD data. Twenty-eight day crude survival among ICHD patients with COVID-19 was approximately 76% and for transplant 75%. Crude survival of those on HT appeared to be worse, at approximately 64% (Fig. 3) . In mutually adjusted models of risk factors of death amongst those who tested positive, the odds of mortality after infection with SARS-CoV-2 was higher among older patients, in particular those aged ≥80 years compared to those aged 60-79 years (OR 1.72, 95% CI 1.35-2.19) (Fig.4) . There was also a higher odds of mortality among patients of Asian ethnicity compared to patients of White ethnicity (OR 1.34, 95% CI 1.07-1.68) and a borderline higher odds among those with diabetes compared to those without (OR 1.14, 95% CI 0.94-1.38). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Fig . 5 ). The number of excess deaths was higher for men than women (573 more deaths in males from January to September 2020 than the 2015-2019 average, compared to only 298 in females), though proportionally the increase in deaths was similar, (26% compared to 24%). Examination of excess deaths across ethnic groups showed a wide disparity. Black patients comprised 9% of the KRT population at the end of 2019 but 20% of the excess deaths. Similarly, Asian patients accounted for 26% of the excess deaths, but only 14% of the KRT population (supplementary Fig 6) . 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 Patients on ICHD were disproportionately affected by COVID-19, with a five-fold infection rate compared to other modalities. Patients from minority ethnic groups and those living in the most socio-economically deprived areas were also more likely to test positive. There was a high mortality amongst those with COVID-19 on all KRT modalities ranging from 25%-36%. Excess mortality was highest in April 2020 at the peak of the pandemic. Overall, excess mortality in 2020 was 36% higher than the average of the 5-year period 2015-2019 and was characterised by wide ethnic disparities. In total, 29% of deaths between March and August 2020 among patients in England who were on KRT at the end of 2019 were attributable to COVID-19. The cumulative incidence of COVID-19 was higher in patients on ICHD than in those with a transplant or on HT. COVID-19 is known to have high intra-hospital transmission rates, 12 putting patients on ICHD at higher risk, because they need to attend hospital to receive their life-saving treatment. From May 2020 onwards some dialysis units in heavily affected areas (primarily London) started testing all ICHD patients, irrespective of whether they were symptomatic, to control transmission. Our analysis showed that higher socioeconomic deprivation is an independent risk factor for testing positive for COVID-19 and proportionally more people of Asian background tested positive compared to other ethnic groups. Also, the risk of testing positive was much higher for those on KRT with diabetes as PRD. Transmission of COVID-19 is facilitated by overcrowded housing and occupations that require close contact with others. In England, the 2011 census showed that Asians, in particular the Bangladeshi group, live in the most deprived neighbourhoods and are most likely to work in at-risk occupations. 13 There were also significant interactions between treatment modality and ethnicity. In particular, the risk 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 of testing positive for COVID-19 was especially significant for White patients on ICHD and for Black patients with transplants. Our findings are in line with studies on the general population. For example, in a metaanalysis, the pooled adjusted relative risk for Asian people was 1.50 (95% CI 1.24-1.83) of White people. 14 Possible explanations include the higher incidence of diabetes 15 and greater socioeconomic deprivation among people of Asian ethnicity. Mortality at 28 days following a positive test was similarly high for patients with a transplant or on ICHD, at about 25%, but was even higher for those on HT, at almost 36%. In March and April 2020 people on HT or with a transplant would only have been tested if they had severe symptoms requiring hospital admission; this was due to a national shortage of test capacity. After adjusting for other risk factors, we found no difference in mortality between people on HT and transplant. Additionally, when we analysed excess deaths by modality, we found that the excess mortality in HT patients was relatively small compared to other modalities. It is therefore possible that the small number of HT patients included in our analysis constituted a subpopulation that had more severe COVID-19 that required hospitalisation and they were therefore more likely to be tested. Older age was the most important risk factor for mortality, with the highest risk being in those aged ≥80 years. The risk was also higher among those on dialysis not listed for kidney transplant at the end of 2019. Despite being important risk factors for testing positive, diabetes as PRD and Asian ethnicity compared to White ethnicity were associated with only a borderline higher risk for mortality. Our results are in line with data from the ERA-EDTA Registry, showing that mortality among patients on KRT was high especially in the elderly. 16 Recent data published by the ERACODA (European Renal Association COVID-19 Database), 17 showed that in dialysis patients, the risk of mortality from COVID-19 was 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 correlated to a more general status of frailty, rather than independent risk factors. 18 Frailty is a term widely used to denote a multidimensional syndrome of loss of reserves (energy, physical ability, cognition, health) that gives rise to vulnerability. It generally affects between 25% and 50% of those aged over 85 years 19 and is especially prevalent among those on dialysis, affecting between 14% and 82% of patients. 20 Older age and frailty status are both recognised as contraindications to transplantation. 21 Odds ratio of mortality from COVID-19 in transplant patients was higher than for individuals on ICHD. As for HT patients, those with a transplant would have only been tested for COVID-19 when requiring hospitalisation, whilst ICHD patients were tested when they developed symptoms to facilitate infection control in dialysis units. According to the latest available Intensive Care National Audit and Research Centre (ICNARC) report, until 31 August 2020, 1.7% of patients admitted to critical care with COVID-19 were patients previously treated with KRT for end stage kidney disease (ESKD), of which 42% invasively ventilated during the first 24 hours from admission and 50% treated with advanced respiratory support during admission. Additionally, until the end of August 2020, the 28-day in-hospital survival of those with COVID-19 admitted to critical care with a previous severe comorbidity, including ESKD treated with KRT, was reported to be approximately 53%. 22 The peak in excess deaths for people on KRT occurred in April 2020, which coincided with excess deaths in the general population. 23 The excess mortality then began to increase again from September onwards, when COVID-19 cases began to increase again, as they did in the general population. However, in the general population, COVID-19 did not feature in the top ten leading causes of death for deaths registered in September 2020. The leading cause of death in England in September 2020 was dementia. 23 In January to September 2020, COVID- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 19 was the underlying cause of death in 11.5% of all deaths that occurred in England in the general population. Among patients on KRT treatment, deaths were particularly high for those with a transplant or on ICHD, at more than double the 5-year average. Excess deaths among KRT patients varied widely according to region, which also mirrored trends in the general population. For the general population, this level of regional inequality was much greater than the inequalities in all-cause mortality rates in previous years. 24 This is the first nationwide analysis to compare COVID-19 outcomes between people on the three KRT modalities in England. In addition, it is the first analysis to compare excess deaths in the KRT population during the first wave of the pandemic, by specific modality, demographics and by region, in one of the countries most severely affected by the pandemic. Unlike published previous analyses, in which data capture was dependent on clinicians submitting data to a central platform, our data represent the entire KRT population in England and all COVID-19 tests that were recorded in these patients. We were unable to adjust the analyses for comorbidities and link our data with hospital data to confirm whether our transplant and HT cohorts were mainly composed of a hospitalised subgroup with worse outcomes. Instead, we used baseline diabetic status for all those on KRT and transplant wait listing status for those on dialysis as surrogates to inform the general health status at baseline of patients. In conclusion, the impact of COVID-19 on the English KRT population has been severe across all three KRT modalities. Patients on KRT are extremely vulnerable and require protection from exposure to infection and urgent vaccination. Similar to the general population, the results also suggest that COVID-19 has widened underlying inequalities in 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 patients with kidney disease. It is therefore important to ensure that interventions which address health inequalities for patients with kidney disease become a priority for the whole renal community. The authors received no specific funding for this work. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 157x250mm (300 x 300 DPI) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 147x254mm (300 x 300 DPI) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 185x233mm (300 x 300 DPI) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance COVID-19 Public Health Emergency of International Concern (PHEIC) Global research and innovation forum Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID 2019) Outbreak in China: Summary of a Report of 72,314 Cases from the Chinese Centre for Disease Control and Prevention Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Factors associated with COVID-19-related death using OpenSAFELY Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis COVID-19 in patients undergoing chronic kidney replacement therapy and kidney transplant recipients in Scotland: findings and experience from the Scottish renal registry English indices of deprivation 2019 SAS Institute Inc. 2016. SAS® 9.4 SQL Procedure User's Guide The novel coronavirus 2019 epidemic and kidneys Office for National Statistics Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis Prevalence of microalbuminuria and hypertension in South Asians and white Europeans with type 2 diabetes: a report from the United Kingdom Asian Diabetes Study (UKADS) Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration An overview of frailty in kidney transplantation: measurement, management and future considerations Frailty in elderly people Frailty: a new comorbidity in kidney transplant candidates? Frailty and the Kidney Transplant Wait List: Protocol for a Multicenter Prospective Study Intensive Care National Audit and Research Centre We thank staff at all adult renal centres in the UK who submit data to the UKRR and who care for kidney patients affected by COVID-19.